<DOC>
	<DOCNO>NCT01068756</DOCNO>
	<brief_summary>The purpose study assess effect rifampin pharmacokinetics dapagliflozin</brief_summary>
	<brief_title>Effect Rifampin Pharmacokinetics Dapagliflozin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy subject Body Mass Index ( BMI ) 18 32 inclusive Women childbearing potential men , age 18 45 Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , electrocardiogram ( ECG ) clinical laboratory determination Glucosuria Abnormal liver function test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>